Spero Therapeutics (SPRO) is scheduled to report Q1 earnings on May 12, 2026. Analysts estimate EPS of $-0.18 and quarterly revenue of N/A.

In the most recent quarter (Q4), Spero Therapeutics reported EPS of $0.53, beating estimates of $-0.25 by 3.12%. Revenue came in at $41.30M, exceeding the estimate of $0.00 by 0.00%.

Spero Therapeutics has beaten EPS estimates in 4 consecutive quarters.

Over the last 4 quarters, Spero Therapeutics has averaged an EPS surprise of 1.26% and a revenue surprise of 0.47%.